報價延遲最少15分鐘:2026/06/10 17:50 EDT
盤後時段
|
||||
|
16.37 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.37
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.23/0.93
|
|
企業價值
881.87M
|
| 資產負債 |
|
每股賬面淨值
5.64
|
| 現金流量 |
|
現金流量率
0.31
|
| 損益表 |
|
收益
107.46M
|
|
每股收益
0.99
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe. |
